Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$1.73
$2.62
$1.07
$6.18
$104.36M1.161.25 million shs819,732 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.46
+1.4%
$1.44
$0.81
$4.07
$24.34M1.4390,863 shs41,793 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$3.08
+0.7%
$2.29
$1.62
$3.84
$101.85M2.021.20 million shs982,470 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$9.83
$15.49
$6.27
$39.75
$88.15M-0.241,748 shs33,273 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
0.00%+8.81%+8.81%-68.72%-13.72%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+1.39%0.00%-16.57%-11.52%+31.53%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
+0.65%-0.32%+36.28%+61.26%+56.35%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
0.00%-10.72%-21.36%-22.78%-29.72%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
$1.73
$2.62
$1.07
$6.18
$104.36M1.161.25 million shs819,732 shs
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$1.46
+1.4%
$1.44
$0.81
$4.07
$24.34M1.4390,863 shs41,793 shs
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$3.08
+0.7%
$2.29
$1.62
$3.84
$101.85M2.021.20 million shs982,470 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$9.83
$15.49
$6.27
$39.75
$88.15M-0.241,748 shs33,273 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
0.00%+8.81%+8.81%-68.72%-13.72%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
+1.39%0.00%-16.57%-11.52%+31.53%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
+0.65%-0.32%+36.28%+61.26%+56.35%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
0.00%-10.72%-21.36%-22.78%-29.72%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
2.00
Hold$5.50217.92% Upside
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
2.25
Hold$10.00584.93% Upside
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
2.50
Moderate Buy$38.251,141.88% Upside
Promis Neurosciences stock logo
PMN
Promis Neurosciences
2.50
Moderate Buy$42.67334.05% Upside

Current Analyst Ratings Breakdown

Latest MRKR, NRXP, ALDX, and PMN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$34.00
4/27/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Boost Price TargetBuy$48.00 ➝ $49.00
4/27/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$45.00
4/20/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$34.00
3/27/2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
Reiterated RatingSell (D-)
3/24/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$34.00
3/24/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$25.00
3/18/2026
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
Reiterated RatingBuyNeutral$10.00 ➝ $2.00
3/17/2026
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
Reiterated RatingBuy
3/16/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$34.00
3/9/2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
Reiterated RatingBuy$34.00
(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/A$0.74 per shareN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
$3.55M6.86N/AN/A$1.01 per share1.45
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
$1.23M82.81N/AN/A($0.54) per share-5.70
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A($0.58) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$33.85M-$0.57N/AN/AN/AN/A-63.75%-41.27%5/13/2026 (Estimated)
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$12.16M-$0.85N/AN/AN/A-343.03%-80.86%-67.04%5/21/2026 (Estimated)
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$28.62M-$1.39N/A2.50N/AN/AN/A-265.03%5/21/2026 (Estimated)
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$39.72M-$19.00N/AN/AN/AN/A-933.63%-295.33%5/11/2026 (Estimated)

Latest MRKR, NRXP, ALDX, and PMN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2026Q1 2026
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.18N/AN/AN/A$0.68 millionN/A
5/21/2026Q1 2026
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.01N/AN/AN/A$25.57 millionN/A
5/13/2026Q1 2026
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.13-$0.06+$0.07-$0.06N/AN/A
5/11/2026Q1 2026
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$1.06N/AN/AN/AN/AN/A
3/23/2026Q4 2025
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
-$0.09$0.19+$0.28$0.19$7.53 million$0.98 million
3/18/2026Q4 2025
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
-$0.21-$0.04+$0.17-$0.04$0.68 million$1.10 million
2/27/2026Q4 2025
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
-$0.14-$0.1074+$0.0326-$0.10$24.25 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/AN/AN/AN/AN/A
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/AN/AN/AN/AN/A
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
N/A
2.58
2.58
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
N/A
8.39
8.39
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
N/A
0.31
0.31
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
0.88
0.88

Institutional Ownership

CompanyInstitutional Ownership
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
59.71%
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
22.39%
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
4.27%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
50.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aldeyra Therapeutics, Inc. stock logo
ALDX
Aldeyra Therapeutics
1060.32 million54.53 millionOptionable
Marker Therapeutics, Inc. stock logo
MRKR
Marker Therapeutics
6016.67 million15.72 millionNot Optionable
NRx Pharmaceuticals, Inc. stock logo
NRXP
NRx Pharmaceuticals
233.07 million30.95 millionOptionable
Promis Neurosciences stock logo
PMN
Promis Neurosciences
58.97 million8.83 millionNot Optionable

Recent News About These Companies

Analysts Set Promis Neurosciences (NASDAQ:PMN) PT at $42.67

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aldeyra Therapeutics stock logo

Aldeyra Therapeutics NASDAQ:ALDX

$1.73 0.00 (0.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.74 +0.02 (+0.87%)
As of 05/8/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Marker Therapeutics stock logo

Marker Therapeutics NASDAQ:MRKR

$1.46 +0.02 (+1.39%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$1.46 0.00 (0.00%)
As of 05/8/2026 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

NRx Pharmaceuticals stock logo

NRx Pharmaceuticals NASDAQ:NRXP

$3.08 +0.02 (+0.65%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$3.08 0.00 (-0.16%)
As of 05/8/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$9.83 0.00 (0.00%)
Closing price 05/8/2026 04:00 PM Eastern
Extended Trading
$10.20 +0.37 (+3.71%)
As of 05/8/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.